Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers

Samdeep K. Mouli, Ramona Gupta, Neil Sheth, Andrew C. Gordon, Robert J. Lewandowski*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Breast cancer is the most common women's malignancy in the United States and is the second leading cause of cancer death. More than half of patients with breast cancer will develop hepatic metastases; this portends a poorer prognosis. In the appropriately selected patient, there does appear to be a role for curative (surgery, ablation) or palliative (intra-arterial treatments) locoregional therapy. Gynecologic malignancies are less common and metastases to the liver are most often seen in the setting of disseminated disease. The role of locoregional therapies in these patients is not well reported. The purpose of this article is to review the outcomes data of locoregional therapies in the treatment of hepatic metastases from breast and gynecologic malignancies.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalSeminars in Interventional Radiology
Issue number1
StatePublished - Mar 1 2018


  • breast cancer
  • chemoembolization
  • gynecologic malignancies
  • interventional radiology
  • liver metastases
  • radioembolization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers'. Together they form a unique fingerprint.

Cite this